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RNase P and ribosomes must interact with similar substrate molecules, tRNA precursors in the case of RNase P and 
aminoacyl-, peptidyl- or free tRNAs in the case of ribosomes. In order to compare the substrate recognition mechanisms 
between ribosomes and RNase P, protein synthesis inhibitors have been assayed for their effect on the catalytic activity 
of the RNA component of Escherichia coli RNase P (MI RNA). Puromycin has an inhibitory effect that could be related 
to similar substrate r cognition mechanisms by rRNA in the ribosome and by M I RNA in RNase P. 
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1. INTRODUCTION 
RNase P is an endoribonuclease which cleaves 
tRNA precursors to generate the 5'-end of mature 
tRNAs [1] leaving 3 ' -OH and 5'-phosphate at the 
cleavage site [2]. In prokaryotes, this enzyme con- 
sists of a catalytic RNA (M1 RNA in Escherichia 
coh) and a protein cofactor [3,4]. Both com- 
ponents are essential in vivo [5], but in vitro the 
RNA component can process tRNA precursors in 
the absence of the protein. This has been 
demonstrated in E. coli [61, Bacillus subtilis [7] and 
Salmonella typhimurium [8]. It is remarkable that 
the E. coli enzyme can cleave not only all the dif- 
ferent tRNA precursors in E. coli, but also those 
from other species [9] and unusual substrate 
molecules [10]. The mechanism by which RNase P 
or its catalytic RNA subunit is able to recognize all 
these different substrates and cleave them at the 
correct site remains unknown. 
Ribosomes must also recognize many different 
tRNA molecules either as aminoacyl-, peptidyl- or 
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free tRNA in a precise way at the A-, P- or E-sites. 
There is now firm evidence that ribosomal RNA 
plays an essential role in tRNA binding during pro- 
tein synthesis I11] and is itself directly and crucially 
involved in the process of translation [12]. Recent- 
ly, a direct and functionally relevant interaction 
between tRNAs and 16 S RNA has been shown 
[13]. 
It has been proposed that a similar mechanism is
used by rRNA and RNase P RNA for recognition 
of tRNAs [14]. This suggestion is based on 
similarities between the secondary structure of 
16 S rRNA and a proposed secondary structure for 
M1 RNA [14]. However, these similarities are not 
supported by other models of the secondary struc- 
ture of M1 RNA [15,16], although no extensive 
comparison of the primary and secondary struc- 
ture between RNase P RNA and rRNAs has been 
made. 
Many antibiotics that inhibit protein synthesis 
interfere with functions related to tRNA binding 
or movement along the ribosome cycle [17]. It has 
been shown that some of these antibiotics bind to 
rRNA at positions involved in tRNA interactions 
[18,19]. 
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In order to investigate whether RNase P RNA 
and rRNA recognize tRNAs  in an analogous way, 
I have studied the inhibit ion of  M1 RNA catalytic 
activity by a number of  protein synthesis in- 
hibitors.  Only puromycin showed a signif icant in- 
h ib i tory effect. The impl icat ions of  this result are 
discussed. 
2. EXPERIMENTAL 
M 1 RNA was prepared by in vitro transcription with T7 RNA 
polymerase using as template plasmid pJA2 digested with FokI, 
as described [20]. The protein cofactor (C5 protein) was 
purified from an overproducing E. coli strain as in [20]. 
32p-labelled substrate was prepared by in vitro transcription 
with T7 RNA polymerase, in the presence of [32p]GTP, of a 
plasmid that contains a synthetic gene for the precursor of 
tRNA TM (Baer, M. and Guerrier-Takada, C., unpublished). 
Run-off digestion of this plasmid after digestion with Fokl pro- 
duces an RNA 131 nucleotides long corresponding to the 
precursor of tRNA TM found in vivo. 
RNase P activity of M1 RNA was assayed in 10 ,ul of a reac- 
tion mixture containing 50 mM Tris-HCl (pH 7.5), 100 mM 
NH4CI, 100 mM MgCl2, 2.4 ng//A of M1 RNA and 
1000-2000 cpm of 32p-labelled substrate. RNase P activity of 
the holoenzyme was assayed in 10/~l of a reaction mixture con- 
taining 50 mM Tris-HCl (pH 7.5), 400 mM NH4C1, l0 mM 
MgC12, 0.3 ng//~l of M1 RNA, 0.6 ng//~l of C5 protein and 
1000-2000 cpm of 32p-labelled substrate. Reaction mixtures 
were incubated with the indicated concentrations of antibiotic 
for 5 rain at 37°C prior to the addition of substrate. After addi- 
tion of the substrate, reaction mixtures were incubated for 
5-10 min at 37°C and the degree of processing measured by 
separating the substrate from the products on 8% acrylamide, 
7 M urea gels and densitometric analysis of the corresponding 
autoradiograms, a  described [20]. 
3. RESULTS AND DISCUSSION 
Var ious protein synthesis inhibitors were 
assayed for their effect on the RNase P activity of  
M1 RNA.  These inhibitors were selected because 
their inhibit ion is related to interference with some 
tRNA funct ion [17] or because their interact ion 
with r ibosomal  RNA is well documented [18,19]. 
Streptomycin,  neomycin,  kanamycin,  kasugamy- 
cin, sparsomycin,  spect inomycin and paramomy-  
cin had no effect on RNase P activity at 
concentrat ions as high as 20 mM. Puromycin  
showed an inhibitory effect ( f ig. l ) .  
Puromyc in  produced 50°70 inhibit ion at a con- 
centrat ion of  -3  mM, with an M1 RNA concentra- 
t ion of  20 nM in the assay mixture. This result 
suggests that,  if inhibit ion is due to the binding of  
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Fig.1. Effect of puromycin on precursor tRNA processing by 
M2 RNA (e) and the RNase P holoenzyme (a). Assays were 
performed as described in section 2 with the indicated 
concentrations of puromycin. Activity is expressed as 
percentage of that obtained in the absence of puromycin. 
one molecule of  puromycin to M1 RNA,  the 
binding constant is of  the order of  103 . This is only 
one order of  magnitude lower than the binding 
constant of  puromycin to r ibosomes (-104) [21]. 
The RNase P holoenzyme is also inhibited at the 
same or slightly lower puromycin concentrat ions 
( f ig. l ) .  This inhibit ion is reduced when lower 
NH4CI concentrat ions are used (Guerr ier -Takada,  
C. and A l tman,  S., personal  communicat ion) .  
Puromyc in  is an analog of  the 3 ' - termina l  end 
of  aminoacy l - tRNA and can funct ion as a 
substrate for the pept idyltransferase activity of  the 
r ibosome. Through its -NH2 group, puromycin can 
be l inked to the C-terminal  end of  a peptidyl  group 
[17]. These data indicate that the pep- 
t idyltransferase center recognizes aminoacyl-  
tRNAs  by the 3 ' -end  of  the tRNA part,  and does 
not require the whole tRNA molecule for recogni- 
t ion. Similarly, RNase P does not require the 
whole tRNA molecule and can process truncated 
tRNA precursors that contain only the aminoacyl  
and T stems of  the tRNA moiety and the T loop 
[23]. 
The 3' CCA end of  tRNAs  has been impl icated 
in the interact ion of  tRNA precursors with M1 
RNA [22,23]. However,  B. subtilis RNase P ap- 
pears to be unaffected by the presence or absence 
of  CCA in their substrates [24]. It would be in- 
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teresting to determine whether puromycin  has any 
effect on B. subtilis RNase P RNA activity. 
In any case, inhibit ion by puromycin  of  tRNA 
precursor  processing by M1 RNA or the RNase P 
holoenzyme suggests that M1 RNA and 23 S RNA 
recognize their substrates in a similar manner.  A 
specific region in 23 S RNA that interacts with 
puromycin  has not been detected, probab ly  due to 
its low binding constant [19], therefore no direct 
compar ison between M1 RNA and a relevant 
region of  23 S RNA can be made at this point. 
However ,  it is noteworthy that there is a strong 
s imi lar i ty in pr imary  and secondary structure be- 
tween the exit site in E. coli 23 S rRNA (posit ions 
2109-2179) and a region in M1 RNA encompass-  
ing posit ions 76-96  and 230-242 (A l tman,  S., per- 
sonal communicat ion) .  Specif ic recognit ion of  the 
3 ' - termina l  adenosine of  a tRNA in the exit site of  
E. coli r ibosomes has been described recently [25]. 
In addit ion,  this work suggests that protein syn- 
thesis inhibitors could become useful tools in the 
analysis of  the catalytic mechanism of  RNase P. 
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